Cost-effectiveness of budesonide Turbuhaler in the treatment of mild-to-moderate asthma in Japan
1999
ABSTRACT Asthma therapy including inhaled corticosteroids (ICS) has been shown to be effective in many parts of the world, but its use is still limited in Japan. A 6-week, randomized, placebo-controlled, clinical trial was therefore undertaken to assess the efficacy of the ICS
budesonideTurbuhaler (
budesonideadministered via the
dry-powder inhalerTurbuhaler) in patients in Japan with mild-to-moderate asthma. Prior to, and during, the study, all concomitant medications, except corticosteroid preparations, were allowed (i.e. all pre-study medication was to be maintained throughout the study). In total, 218 patients randomized to receive
budesonideTurbuhaler 200μg/day ( n = 53), 400μg/day ( n = 55), 800μg/day ( n = 57) or placebo ( n = 53) were included in the analysis. Due to the increased demand and interest for
health economicdata in Japan, this retrospective
cost-effectiveness analysisreports on the economic impact of
budesonideTurbuhaler compared with placebo (i.e. usual care), based on this clinical trial. At each dosage,
budesonideTurbuhaler was significantly more effective than the placebo, according to the number of symptom-free and episode-free days. The number of emergency visits, days of lost production and days of hospitalization were all lower in the
budesonideTurbuhaler groups, leading to significantly ( P
Keywords:
-
Correction
-
Source
-
Cite
-
Save
20
References
7
Citations
NaN
KQI